291 active not recruiting. 291 Phase 1, 120 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 291 | Active not recruiting 291 |
| Phase 2 | 120 | Active not recruiting 120 |
Follow Digestive System Diseases: new trials by email Literature Review of Digestive System Diseases trials Research Report on Digestive System Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1 Relative Bioavailability Study of a VX-581 Tablet Formulation VX-581 - Cystic Fibrosis | Phase 1 | Active not recruiting | Vertex Pharmaceuticals Incorporated | 16 | 2026-09-23 | 2026-10-27 |
| Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments Opnurasib, TNO155, trametinib - Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation | Phase 1 / Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 25 | 2026-06-08 | 2026-10-23 |
| Molecular Imaging of Fibroblast Activation Protein Expression Using Labeled Technetium-99m HYNIC-FAPI [99mTc]Tc-HYNIC-FAPI - Lung Cancer (Locally Advanced or Metastatic), Pancreas Cancer, Metastatic | Phase 1 | Active not recruiting | Tomsk National Research Medical Center of the Russian Academy of Sciences | 15 | 2026-02-26 | 2026-06-25 |
| The Prospective Improved Vitamin D Study for Inflammatory Bowel Disease Patients Vitamin D3 (Cholecalciferol) - Ulcerative Colitis (UC), IBD (Inflammatory Bowel Disease) | Phase 1 | Active not recruiting | Terry Ponich | 150 | 2025-11-05 | 2026-10-05 |
| A Study of PALI-2108 in Healthy Volunteers, Patients With Ulcerative Colitis, and Patients With Fibrostenosing Crohn's Disease PALI-2108 - Fibrostenotic Crohn's Disease | Phase 1 | Active not recruiting | Palisade Bio | 6 | 2025-10-17 | 2026-02-23 |
| A Research Study of a Potential New Medicine (NNC4005-0001) for Liver Disease in Adult Participants With Increased Body Weight and Liver Fat NNC4005-001, Placebo - Fatty Liver Disease | Phase 1 | Active not recruiting | Novo Nordisk A/S | 29 | 2025-10-08 | 2026-10-13 |
| A Study to Evaluate Blood Levels of Bepirovirsen in Adult Participants With Severe or Moderate Kidney Disease Bepirovirsen - Hepatitis B | Phase 1 | Active not recruiting | GlaxoSmithKline | 32 | 2025-09-26 | 2026-05-22 |
| A Study of SN2001 Dose, Safety & Immunogenicity in Healthy Adults SN2001 - Chronic Hepatitis B Infection | Phase 1 | Active not recruiting | Chimivac INC | 36 | 2025-08-19 | 2026-10-13 |
| A Study of Narmafotinib Given in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer narmafotinib ascending doses, narmafotinib dose comparison - Pancreatic Cancer Metastatic | Phase 1 / Phase 2 | Active not recruiting | Amplia Therapeutics Limited | 67 | 2025-08-18 | 2026-05-05 |
| Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers Computed Tomography, Fludeoxyglucose F-18, Gallium Ga 68 FAPi-46 - Anal Carcinoma, Bladder Carcinoma | Phase 1 | Active not recruiting | Jonsson Comprehensive Cancer Center | 30 | 2025-08-01 | 2026-10-20 |
| Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors BL-M05D1 - Gastric Adenocarcinoma, Advanced Pancreatic Ductal Adenocarcinoma | Phase 1 | Active not recruiting | SystImmune Inc. | 160 | 2025-07-30 | 2026-08-05 |
| A Study of SH006 Injection Combination Therapy in Patients With Advanced Solid Tumors SH006 - Liver Cancer | Phase 1 | Active not recruiting | Nanjing Sanhome Pharmaceutical, Co., Ltd. | 50 | 2025-07-01 | 2026-01-23 |
| Effective Dose and Safety of Esketamine During Ultrasound-guided Hepatic Tumor Thermal Ablation Intravenous esketamine using Dixon's up-and-down sequential method, Intravenous the dose of esketamine ED95, Intravenous fentanyl 1 μg∙kg-1 - Hepatic Neoplasm, Hepatic Cancer | Phase 1 / Phase 2 | Active not recruiting | The First Affiliated Hospital of Xiamen University | 79 | 2025-06-29 | 2025-09-11 |
| A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation ARV-806 - KRAS G12D Mutation, Advanced Solid Cancer | Phase 1 / Phase 2 | Active not recruiting | Arvinas Inc. | 76 | 2025-05-29 | 2026-09-16 |
| A Long-term Study to Monitor the Health Status of People With Cystic Fibrosis Who Took Part in a Previous Study With BI 3720931 (Lenticlair™-ON) BI 3720931 - Cystic Fibrosis | Phase 1 / Phase 2 | Active not recruiting | Boehringer Ingelheim | 5 | 2025-05-20 | 2026-04-14 |
| Phase I Trial of QH-1A Hybrid Bio-Artificial Liver With Ex Vivo Blood-Purifying MSCs in Acute-on-Chronic Liver Failure Combining the QH-1A bioartificial liver device with mesenchymal stem cells for blood purification（4 hours）, Combining the QH-1A bioartificial liver device with mesenchymal stem cells for blood purification（6 hours）, Combining the QH-1A bioartificial liver device with mesenchymal stem cells for blood purification（8 hours） - Acute-On-Chronic Liver Failure | Phase 1 | Active not recruiting | Third Affiliated Hospital, Sun Yat-Sen University | 15 | 2025-05-07 | 2025-05-30 |
| Study for AZD4360 in Participants With Advanced Solid Tumours AZD4360 - Gastric Cancer, Gastroesophageal Junction Cancer | Phase 1 / Phase 2 | Active not recruiting | AstraZeneca | 31 | 2025-04-29 | 2026-07-31 |
| A Phase 1b Study of GKL-006 Injection in Patients With Unresectable Hepatocellular Carcinoma GKL-006 Injection, Transarterial chemoembolization (TACE) - Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Cancer | Phase 1 | Active not recruiting | Beijing Gene Key Life Technology Co., Ltd | 6 | 2025-04-03 | 2026-07-20 |
| Study to Evaluate Safety, Tolerability and Pharmacokinetics of IDB-011 IDB-011 dose level 1, IDB-011 dose level 2, IDB-011 dose level 3 - Rift Valley Fever | Phase 1 | Active not recruiting | IDBiologics, Inc. | 40 | 2025-04-02 | 2026-03-25 |
| A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation INCB186748, Cetuximab, GEMNabP - Solid Tumors | Phase 1 | Active not recruiting | Incyte Corporation | 30 | 2025-03-27 | 2026-08-25 |
Showing 20 of 291. Sign in to see all of them.
Colorectal Neoplasms (103) · Pancreatic Neoplasms (74) · Carcinoma, Non-Small-Cell Lung (66) · Stomach Neoplasms (61) · Ovarian Neoplasms (42) · Carcinoma, Hepatocellular (38) · Melanoma (34) · Esophageal Neoplasms (31) · Neoplasm Metastasis (31) · Neoplasms (28) · Breast Neoplasms (27) · Colonic Neoplasms (27) · Squamous Cell Carcinoma of Head and Neck (27) · Lung Neoplasms (25) · Carcinoma, Renal Cell (21)
Digestive System Neoplasms (251) · Neoplasms by Site (248) · Neoplasms (226) · Gastrointestinal Diseases (189) · Gastrointestinal Neoplasms (168) · Intestinal Diseases (130) · Colonic Diseases (119) · Intestinal Neoplasms (116) · Rectal Diseases (111) · Neoplasms by Histologic Type (110) · Endocrine System Diseases (108) · Endocrine Gland Neoplasms (105) · Neoplasms, Glandular and Epithelial (93) · Carcinoma (91)
pembrolizumab (26) · Gemcitabine (21) · Nivolumab (20) · Fluorouracil (19) · Bevacizumab (17) · Specimen Handling (16) · Leucovorin (15) · Magnetic Resonance Spectroscopy (15) · Cetuximab (14) · Oxaliplatin (14) · Biopsy (13) · Paclitaxel (13) · 130-nm albumin-bound paclitaxel (12) · Carboplatin (12) · Irinotecan (12)
National Cancer Institute (NCI) (20) · M.D. Anderson Cancer Center (18) · AstraZeneca (8) · Eli Lilly and Company (7) · City of Hope Medical Center (5) · GlaxoSmithKline (5) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (5) · Memorial Sloan Kettering Cancer Center (4) · Novartis Pharmaceuticals (4) · TORL Biotherapeutics, LLC (4) · University of Southern California (4) · AbbVie (3) · Baylor College of Medicine (3) · Mayo Clinic (3) · Ono Pharmaceutical Co., Ltd. (3)
United States (207) · Spain (56) · China (50) · France (45) · Canada (43) · Australia (42) · South Korea (41) · Japan (36) · United Kingdom (36) · Italy (32) · Germany (26) · Belgium (23) · Netherlands (18) · Taiwan (18) · Denmark (13)
Project Leader (3) · Caroline Labib, PharmD (2) · Daneng Li (2) · David Hong, MD (2) · Jeremie Calais (2) · Liza C Villaruz (2)
PMID 37788341, PMID 10870744, PMID 11165371, PMID 11786502, PMID 14621285, PMID 15647484, PMID 15800228, PMID 16508405, PMID 17123731, PMID 17237664, PMID 17433624, PMID 17635557, PMID 17853395, PMID 18294378, PMID 18362258, PMID 18378801, PMID 18419722, PMID 18619874, PMID 18774343, PMID 19409861, PMID 19789074, PMID 20031953, PMID 20086062, PMID 21029787, PMID 21148579, PMID 21249671, PMID 21412914, PMID 21765969, PMID 22225488, PMID 22285199, PMID 22336864, PMID 22494121, PMID 22898544, PMID 24661411, PMID 24867013, PMID 25221944, PMID 25418676, PMID 25872113, PMID 25957198, PMID 26029937, PMID 26987082, PMID 27407096, PMID 28074005, PMID 28106092, PMID 28119481, PMID 28409480, PMID 28767350, PMID 29671994, PMID 29769209, PMID 30325859
2023 (15), 2019 (5), P30CA033572 (4), 2025 (3), P30CA014089 (3), UM1CA186644 (3), UM1CA186690 (3), UM1CA186709 (3), 2017 (2), 2018 (2), P30CA015083 (2), P30CA016672 (2), U01CA062490 (2), UM1CA186689 (2), UM1CA186716 (2)